

NEXT SCIENCE®

XPERIENCE™ cleared for sale in Canada

Sydney, Australia, Friday, 26 August 2022: Next Science Limited (ASX:NXS) (**Next Science / Company**) announces that Health Canada has given licensing approval for XPERIENCE™, Next Science's advanced irrigation product, to be sold in Canada effective immediately.

Next Science launched XPERIENCE™ in the US in April 2021 and applied for licensing in Canada in May 2021.

The Health Canada licensing approval allows Next Science to sell XPERIENCE™ throughout Canada.

With more than a million surgical procedures performed in Canada annually¹, the Company is working on plans to launch XPERIENCE™ in the Canadian market during H2 2022. Next Science will build a sales agent distribution network and will commence a major randomised control study which will compare XPERIENCE™ against current standard of care and the rate of post operative infections. The principal investigator for the study has been engaged and is based out of the University of Ottawa.

There were over 110,000 hip and knee surgeries completed in Canada in 2020/2021² and more than 50,000 orthopaedic trauma surgeries³. All surgical groups were reduced in number from previous years due to the negative impact of COVID on hospital activity.

Managing Director Judith Mitchell commented: "We are thrilled to see this licence come through and can now move to both commercial and clinical research activity in Canada. We look forward to the differences we can show in such a well-documented health system."

Approved and authorised for release by Next Science's Managing Director.

Further information:

Judith Mitchell

Managing Director, Next Science Limited

Phone: +61 2 8607 5124

Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory

Phone: +61 400 248 080

Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio™ is a unique, non-toxic technology with proven efficacy in

¹https://www.cmpa-acpm.ca/static-assets/pdf/research-and-policy/system-and-practice-improvement/SSC_Detailed_Analysis_Report-e.pdf

²<https://www.cihi.ca/sites/default/files/document/hip-knee-replacements-in-canada-cjrr-annual-report-2020-2021-en.pdf>

³<https://www.statista.com/statistics/498422/inpatient-surgery-total-number-canada-by-type/>

eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio™ technology. Website: www.nextscience.com.

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may” and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management, and could cause Next Science’s actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.